经导管瓣膜介入临床试验数据
Transcatheter Valve Trial Data
09/11 13:30-14:45
主会场·国际场（5楼 水晶厅 -Ⅰ&Ⅳ） (Main Arena - International (5F Crystal Hall - I & IV))
-
13:30-14:45
-
13:30-14:45
-
13:30-14:45学习目标 • 理解经导管瓣膜治疗不断壮大的真实世界证据基础 • 了解国际经导管瓣膜病介入治疗器械在中国的真实世界临床结果 • 认识国产经导管瓣膜病介入治疗器械的实际临床表现Session Objectives • Understand the growing real-world evidence base for transcatheter valve therapy • Appreciate the clinical performance of international transcatheter valve devices in Chinese patients • Know more about the clinical performance of domestic transcatheter valve devices
-
13:30-13:31
-
13:31-13:39Evolut PRO/PRO+ 系统 TAVI 在中国 3500 例患者中的真实世界临床结果Real-world clinical outcomes of TAVI with the Evolut PRO/PRO+ systems in 3500 Chinese patients
-
13:39-13:43讨论与观众互动Discussion and audience interaction
-
13:43-13:51VitaFlow 电动自扩张系统 TAVI 的十年结果Ten-year outcomes after TAVI with the motorized self-expanding VitaFlow system
-
13:51-13:55讨论与观众互动Discussion and audience interaction
-
13:55-14:03ProStyle 干瓣自扩张系统 TAVI 的四年随访结果Four-year outcomes after TAVI with the dry-tissue self-expanding ProStyle system
-
14:03-14:07讨论与观众互动Discussion and audience interaction
-
14:07-14:15TAVI 瓣膜的长期耐久性：来自随机与登记研究的证据Long-term durability of TAVI valve: evidence from randomized and registry studies
-
14:15-14:19讨论与观众互动Discussion and audience interaction
-
14:19-14:27GeminiOne 系统 TEER 的两年结果Two-year outcomes after TEER with the GeminiOne system
-
14:27-14:31讨论与观众互动Discussion and audience interaction
-
14:31-14:39DragonFly TEER 系统治疗二尖瓣与三尖瓣反流的临床结果Clinical outcomes of the DragonFly TEER systems in mitral and tricuspid regurgitation
-
14:39-14:43讨论与观众互动Discussion and audience interaction
-
14:43-14:45